Gilead Sciences Inc. (GILD) Shares Bought by Ajo LP
Ajo LP increased its stake in shares of Gilead Sciences Inc. (NASDAQ:GILD) by 4.8% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,146,418 shares of the biopharmaceutical company’s stock after buying an additional 143,368 shares during the period. Gilead Sciences makes up about 1.2% of Ajo LP’s portfolio, making the stock its 20th largest position. Ajo LP owned 0.24% of Gilead Sciences worth $262,474,000 at the end of the most recent reporting period.
Other institutional investors also recently modified their holdings of the company. Joel Isaacson & Co. LLC increased its position in Gilead Sciences by 20.8% in the second quarter. Joel Isaacson & Co. LLC now owns 1,310 shares of the biopharmaceutical company’s stock valued at $109,000 after buying an additional 226 shares during the period. Jolley Asset Management LLC increased its position in Gilead Sciences by 67.3% in the second quarter. Jolley Asset Management LLC now owns 1,696 shares of the biopharmaceutical company’s stock valued at $141,000 after buying an additional 682 shares during the period. Loomis Sayles & Co. L P increased its position in Gilead Sciences by 23.3% in the first quarter. Loomis Sayles & Co. L P now owns 1,591 shares of the biopharmaceutical company’s stock valued at $146,000 after buying an additional 301 shares during the period. North Star Investment Management Corp. increased its position in Gilead Sciences by 47.8% in the second quarter. North Star Investment Management Corp. now owns 2,165 shares of the biopharmaceutical company’s stock valued at $181,000 after buying an additional 700 shares during the period. Finally, Stanley Laman Group Ltd. purchased a new stake in shares of Gilead Sciences during the second quarter worth about $205,000. 77.94% of the stock is currently owned by institutional investors.
Gilead Sciences Inc. (NASDAQ:GILD) traded down 1.77% during trading on Monday, reaching $77.72. 3,843,812 shares of the company’s stock were exchanged. Gilead Sciences Inc. has a 12 month low of $76.67 and a 12 month high of $111.11. The stock has a market cap of $102.56 billion, a PE ratio of 6.82 and a beta of 1.10. The firm has a 50 day moving average of $79.40 and a 200-day moving average of $85.53.
Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Monday, July 25th. The biopharmaceutical company reported $3.08 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $3.02 by $0.06. Gilead Sciences had a return on equity of 106.75% and a net margin of 50.50%. The firm earned $7.78 billion during the quarter, compared to the consensus estimate of $7.80 billion. During the same quarter in the previous year, the company posted $3.15 earnings per share. The business’s revenue was down 5.7% on a year-over-year basis. On average, equities research analysts anticipate that Gilead Sciences Inc. will post $11.76 earnings per share for the current fiscal year.
The business also recently disclosed a quarterly dividend, which was paid on Thursday, September 29th. Shareholders of record on Friday, September 16th were given a $0.47 dividend. The ex-dividend date of this dividend was Wednesday, September 14th. This represents a $1.88 annualized dividend and a yield of 2.38%. Gilead Sciences’s payout ratio is currently 16.56%.
GILD has been the topic of a number of analyst reports. Credit Suisse Group AG reduced their price objective on shares of Gilead Sciences from $115.00 to $95.00 and set an “outperform” rating on the stock in a research note on Wednesday, September 14th. Morgan Stanley reiterated a “hold” rating and set a $103.00 price objective on shares of Gilead Sciences in a research note on Wednesday, June 15th. Robert W. Baird reiterated an “outperform” rating and set a $135.00 price objective on shares of Gilead Sciences in a research note on Monday, June 6th. Jefferies Group reiterated a “hold” rating on shares of Gilead Sciences in a research note on Thursday, August 25th. Finally, Piper Jaffray Cos. reiterated an “overweight” rating on shares of Gilead Sciences in a research note on Tuesday, August 16th. Ten investment analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and two have issued a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $105.00.
In related news, CEO John F. Milligan sold 112,000 shares of the company’s stock in a transaction that occurred on Tuesday, July 5th. The stock was sold at an average price of $84.33, for a total transaction of $9,444,960.00. Following the completion of the transaction, the chief executive officer now owns 1,170,963 shares in the company, valued at $98,747,309.79. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, EVP Paul Rutherford Carter sold 2,000 shares of the company’s stock in a transaction that occurred on Monday, August 1st. The shares were sold at an average price of $79.81, for a total value of $159,620.00. Following the transaction, the executive vice president now owns 64,122 shares of the company’s stock, valued at approximately $5,117,576.82. The disclosure for this sale can be found here. 1.40% of the stock is owned by company insiders.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines in areas of unmet medical need. The Company’s principal areas of focus include human immunodeficiency virus (HIV), liver diseases, such as chronic hepatitis C virus infection and chronic hepatitis B virus infection, cardiovascular, hematology/oncology and inflammation/respiratory.
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.